1. Seemungal TA, Wedzicha JA. Update in Chronic Obstructive Pulmonary Disease 2014. Am J Respir Crit Care Med, 2015, 192(9): 1036-1044.
[2]
2. Andrianopoulos V. Six-minute walk distance in patients with chronic obstructive pulmonary disease: Which reference equations should we use?. Chron Respir Dis, 2015, 12(2): 563-568.
[3]
3. Martinez FJ, Calverley PMA, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet, 2015, 385(9971): 857-866.
[4]
4. Postma DS, BushA, Vand BM. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet, 2015, 385(9971): 899-909.
[5]
5. Manalan K, Rashid T, Singanayagam A. Antibiotic treatment in exacerbations of chronic obstructive pulmonary disease: recent trial results. Clinical Investigation, 2015, 5(2): 189-204.
[6]
6. Xu XL, Wu XQ, Ye JR, et al. Molecular Characterization and Functional Analysis of Three Pathogenesis-Related Cytochrome P450 Genes from Bursaphelenchus xylophilus (Tylenchida: Aphelenchoidoidea). Int J Mol Sci, 2015, 16(3): 5216-5234.
[7]
7. Coelho A, Fraichard S, Le GG, et al. Cytochrome P450-dependent metabolism of caffeine in Drosophila melanogaster. PLOS One, 2015, 10(2): 168-170.
[8]
8. Cheng SL, Yu CJ, Yang PC. Genetic Polymorphisms of Cytochrome P450 and Matrix Metalloproteinase in Chronic Obstructive Pulmonary Disease. Biochem Genet, 2015, 47(7): 591-601.
[9]
9. Gaspar P, Moreira J, Kvitko K, et al. CYP1A1, CYP2E1, GSTM1, GSTT1, GSTP1, and TP53 polymorphisms: do they indicate susceptibility to chronic obstructive pulmonary disease and non-small-cell lung cancer?. Genetics & Molecular Biology, 2004, 27(2): 133-138.
[10]
10. Korytina GF, Akhmadishina LZ, Kochetova OV, et al. Association of cytochrome P450 genes polymorphisms (CYP1A1 and CYP1A2) with the development of chronic obstructive pulmonary disease in Bashkortostan. Mol Biol (Mosk), 2008, 42(1): 32-41.
[11]
11. Putra AC, Tanimoto K, Arifin M, et al. Genetic variations in detoxification enzymes and HIF-1α in Japanese patients with COPD. Clin Respir J, 2013, 7(1): 7-15.
[12]
12. Vibhuti A, Mishra AA. CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with oxidative stress in COPD. Clin Chim Acta, 2010, 411(7-8): 474-480.
[13]
13. Yang L, Li F, Yan M, et al. Association of the CYP1A1 MspI and TNFα-308 polymorphisms with chronic obstructive pulmonary disease in Inner Mongolia. Genetics & Molecular Research Gmr, 2014, 13(2): 3209-3217.
[14]
14. Kuo HW, Liu SC, Tsou HH, et al. CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics, 2016, 14(10): 1191-1201.
[15]
15. Liu C, Jiang Z, Deng QX, et al. Meta-analysis of association studies of CYP1A1 genetic polymorphisms with digestive tract cancer susceptibility in Chinese.Asian Pac J Cancer Prev, 2014, 15(11): 4689-4695.
[16]
16. Lu J, Zhao Q, Zhai YJ, et al. Genetic polymorphisms of CYP1A1 and risk of leukemia: a meta-analysis. Onco Targets Ther, 2015, 8: 2883-2902.
[17]
17. Lu Y, Zhang XL, Xie L, et al. Lack of association between CYP1A1 polymorphisms and risk of bladder cancer: a meta-analysis. APJCP, 2014, 15(9): 4071-4077.
[18]
18. Ding G, Xu W, Liu H, et al. CYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysis. Mol Biol Rep, 2013, 40(5): 3483-3491.
20. Wang CD, Chen N, Huang L, et al. Impact of CYP1A1 Polymorphisms on Susceptibility to Chronic Obstructive Pulmonary Disease: A Meta-Analysis. Biomed Res Int, 2014, 2015(3): 1-9.
[21]
21. Xu J L, Xia R, Sun L, et al. Association of CYP1A1 MspI polymorphism with oral cancer risk in Asian populations: a meta-analysis. Genet Mol Res, 2015, 15(2): 1-6.
[22]
22. Chappell SL, Daly L, Lotya J, et al. The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: a replication case-control study. BMC Med Genet, 2011, 12(1): 1-7.
24. Zhou X, Baron RM, Hardin M, et al. Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. Hum Mol Genet, 2015, 21(6): 1325-1335.
[25]
25. Shukla RK, Kant S, Bhattacharya S, et al. Association of genetic polymorphism of GSTT1, GSTM1 and GSTM3 in COPD patients in a north Indian population. COPD, 2014, 8(3): 167-172.
